HPR62 Making the Cut: An Assessment of ICER’s Acceptance of Evidence in Unsupported Price Increase Reports

Abstract

The Institute for Clinical and Economic Review’s (ICER) Unsupported Price Increase (UPI) reports aim to identify drugs with substantial price increases without adequate evidence to justify the increases. ICER’s methodology and criteria for accepting evidence have received critique, and there is limited research on how different types of manufacturer-submitted evidence are appraised. Our objectives were to review ICER’s determinations for manufacturer-submitted evidence and identify acceptance and rejection trends.